Cencora, Inc. (NYSE: COR) has announced the pricing of $500 million aggregate principal amount of its 4.625% senior notes due December 15, 2027, $600 million aggregate principal amount of its 4.850% senior notes due December 15, 2029, and $700 million aggregate principal amount of its 5.150% senior notes due February 15, 2035. This offering is part of an underwritten registered public offering and is expected to close on December 9, 2024, subject to customary closing conditions.
The company intends to use the net proceeds from this offering to finance the acquisition of the majority of Retina Consultants of America and related fees and expenses, as well as for general corporate purposes.
Cencora's joint book-running managers for the offering are BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC.
Cencora, a leading global pharmaceutical solutions organization, has an annual revenue of more than $290 billion and is ranked #10 on the Fortune 500 and #24 on the global Fortune 500.
This press release contains forward-looking statements that are subject to various risks and uncertainties. These statements are based on management's current expectations and are subject to change. The company's actual results may differ materially from those indicated by these forward-looking statements.
Following these announcements, the company's shares moved -0.6%, and are now trading at a price of $248.55. For more information, read the company's full 8-K submission here.
